ARIX BIOSCIENCE PLC Notice of Results & Investor Presentation

Directive transparence : information réglementée

03/08/2022 08:00

Arix Bioscience PLC (ARIX)
Notice of Results & Investor Presentation

03-Aug-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc


Notice of Results & Investor Presentation


LONDON, 3 August 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, will announce its results for the six months ended 30 June 2022 on Wednesday 10 August 2022.


Analyst Briefing: 9:00am, Wednesday 10 August


Management will host a virtual analyst presentation followed by a Q&A session at 9:00am BST on Wednesday 10 August. Analysts wishing to join should register their interest by contacting arix@powerscourt-group.com.


Investor Presentation: 2:00pm, Wednesday 10 August


Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 2:00pm BST on Wednesday 10 August.


The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the 'Investor Meet Company' dashboard up until 9:00 a.m. on Wednesday 10 August or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/arix-bioscience-plc/register-investor


Investors who already follow Arix on the Investor Meet Company platform will automatically receive an invitation to the event.





For more information on Arix, please contact:


Arix Bioscience plc

+44 (0)20 7290 1050



Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446



About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.


We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com



ISIN: GB00BD045071
Category Code: NOR
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 178861
EQS News ID: 1411893

End of Announcement EQS News Service


15/09/2022 08:00
12/08/2022 08:00
10/08/2022 19:05
10/08/2022 18:46
10/08/2022 08:01
10/08/2022 08:00
03/08/2022 08:00
22/07/2022 08:00
22/06/2022 17:45
22/06/2022 08:00